Physician profile
Sumit Kalra
NPI 1497941025
$2,427.87
in general payments reported to CMS, 2019-2025
19 companies · $644 in 2025
The $644 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $106 · 2021: $595 · 2022: $175 · 2023: $314 · 2024: $398 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,355.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $396.87 | 2019-2022 | |
| Boston Scientific Corporation | $395.95 | 2020-2025 | Watchman Flx |
| Amgen INC. | $371.62 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $220.63 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $154.55 | 2021-2024 | Xarelto |
| Edwards Lifesciences Corporation | $142.84 | 2021 | |
| Esperion Therapeutics, INC. | $125.03 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $113.38 | 2020-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $110.81 | 2021-2024 | Farxiga |
| Heartflow, INC. | $68.69 | 2023 | Ffrct |
| Kiniksa Pharmaceuticals International, Plc | $64.11 | 2024 | Arcalyst |
| Cvrx, INC. | $49.61 | 2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.06 | 2023-2024 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $42.81 | 2022-2023 | Arcalyst |
| Kestra Medical Technology Services, INC. | $35.76 | 2023-2025 | Assure Wcd |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $33.10 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.31 | 2025 | Jardiance |
| Pfizer INC. | $20.46 | 2024 | |
| Irhythm Technologies, INC. | $13.28 | 2024 | Zio Monitor, Zio Xt Patch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Kalra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.